Search

Background: MDR-TB is a growing concern in meeting global targets for TB control. In high-income low TB-incidence countries, a disproportionate number of MDR-TB cases occur in migrant (“foreign born”) populations, with concerns about low adherence rates in these patients compared to the host non-migrant population. Tackling MDR-TB in this context may therefore require unique approaches. We conducted a systematic review and meta-analysis to identify and synthesise data on MDR-TB treatment adherence in migrant patients to inform evidence-based strategies to improve care pathways and health outcomes in this group. Methods: This systematic review and meta-analysis was conducted in line with PRISMA guidelines (PROSPERO 42017070756). The databases Embase, Medline, Global Health and PubMed were searched to 24 May 2017 for primary research reporting MDR-TB treatment adherence and outcomes in migrant populations, with no restrictions on dates or language. Meta-analysis was conducted using random-effects models. Results: From 413 papers identified in the database search, 15 studies reporting on MDR-TB treatment outcomes for 258 migrants and 174 non-migrants, were included in the systematic review and meta-analysis. The estimated rate of adherence to MDR-TB treatment across migrant patients was 71% (95% CI: 58-84%), with non-adherence reported among 20% (95% CI: 4-37%) of migrant patients. A key finding was there were no Differences in estimated rates of adherence (RR = 1.05; 95% CI: 0.82-1.34) or non-adherence (RR = 0.97; 95% CI:0.79-1.36) between migrants and non-migrants. Conclusions: MDR-TB treatment adherence rates among migrants in high-income low TB-incidence countries are approaching global targets for treatment success (75%), and are comparable to rates in non-migrants. The findings highlight that only just over 70% of migrant and non-migrant patients adhere to MDR-TB treatment. The results point to the importance of increasing adherence in all patient groups, including migrants, with an emphasis on tailoring care based on social risk factors for poor adherence. We believe that MDR-TB treatment targets are not ambitious enough.